A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2022-09-26
Adverse events
Grade 2 Anaemia — outcome: UNKNOWN; onset 2022-10-29 (study day 21); relationship: not assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-11-02 (study day 25); relationship: N
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-12-31 (study day 84); relationship: not assessed
Grade 3 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-05-18 (study day 222); relationship: not assessed; serious criteria: hospitalization
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-07-08 (study day 273); relationship: N
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-07-28 (study day 293); relationship: N
Data queries
No data queries.